COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: Group A (turmeric) receives 3 tablets of 500 mg of turmeric (curcuma) daily with standard treatment of Covid-19. The medicine will be given to the person by the the
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years or older Definitive diagnosis of Covid-19 disease (positive PCR, CT scan) Absence of chronic hepatitis Absence of cirrhosis Absence of cholestatic liver disease Absence of gallbladder inflammation Absence of peptic ulcers Lack of sensitivity to ginger Lack of sensitivity to turmeric Absence of women during pregnancy and lactation Do not take anti-inflammatory drugs such as Colchicine and Actemra
Exclusion criteria
Exclusion criteria: Reluctance to continue participating in research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Fever will be measured using a mercury thermometer.;Cough. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of cough will be measured using the visual analog scale (VAS).;Fatigue. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of fatigue will be measured using the visual analog scale (VAS).;Sore throat. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of sore throat will be measured using the visual analog scale (VAS).;Nasal congestion. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of nasal congestion will be measured using the visual analog scale (VAS).;Diarrhea. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: The severity of diarrhea will be assessed by the number of times a day.;Dyspnea. Timepoint: From the beginning of the intervention until the fifth day. Method of measurement: Severity of dyspnea will be measured using the visual analog scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count (CBC). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits.;Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits.;C-reactive protein (CRP). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits.;Lactate dehydrogenase (LDH). Timepoint: At the beginning of the study (before the intervention) and at the end of the study (completion of the intervention). Method of measurement: Using the relevant laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Babamohamadi
Semnan University of Medical Sciences
Outcome results
None listed